News tagged with lenalidomide

Related topics: patients , multiple myeloma

Treatment beneficial in smoldering multiple myeloma

(HealthDay)—For patients with smoldering multiple myeloma, treatment with lenalidomide plus dexamethasone correlates with delayed progression and improved survival, according to a study published in the ...

Aug 01, 2013
popularity not rated yet | comments 0

New drug improves survival in multiple myeloma relapse

Researchers at Moffitt Cancer Center and colleagues have investigated the safety, efficacy and the maximum tolerated dose of pomalidomide for patients with multiple myeloma who have disease relapsed after treatments with ...

Jan 24, 2013
popularity not rated yet | comments 0

New drug shows promise for myeloma patients

(HealthDay) -- Three new studies confirm that the drug lenalidomide can significantly lengthen the time that people with multiple myeloma experience no worsening of their disease, either after having a stem ...

May 09, 2012
popularity 5 / 5 (1) | comments 0 | with audio podcast

Chemo combination promising for multiple myeloma

(HealthDay) -- For patients with relapsed or refractory multiple myeloma, combination treatment with elotuzumab, lenalidomide, and low-dose dexamethasone is generally well tolerated, with encouraging response ...

May 02, 2012
popularity not rated yet | comments 0

Study urges caution with lenalidomide dosage

An early phase multiple myeloma trial has unexpectedly revealed that the drug lenalidomide interacts with another protein in cells that affect its dose level in the body, say researchers at the Ohio State University Comprehensive ...

Aug 08, 2011
popularity not rated yet | comments 0 | with audio podcast

Lenalidomide

Lenalidomide ( /lɛnəˈlɪdɵmaɪd/), initially known as CC-5013 and marketed as Revlimid by Celgene, is a derivative of thalidomide introduced in 2004.

It was initially intended as a treatment for multiple myeloma, for which thalidomide is an accepted therapeutic treatment. Lenalidomide has also shown efficacy in the class of hematological disorders known as myelodysplastic syndromes (MDS). Lenalidomide and bortezomib are considered therapeutic breakthroughs in the treatment of myeloma, which generally carries a poor prognosis.

This text uses material from Wikipedia licensed under CC BY-SA